Cuevas-García Carlos, Calderón-Vallejo Alejandra, Berrón-Ruiz Laura
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades, Ciudad de México, México.
Rev Alerg Mex. 2020 Oct-Dec;67(4):338-349. doi: 10.29262/ram.v67i4.828.
The clinical manifestations of COVID-19 are reminiscent of those of acute respiratory distress syndrome induced by cytokine release syndrome and secondary hemophagocytic lymphohistiocytosis that is observed in patients with other coronaviruses such as SARS-CoV and MERS-CoV. Neurologists face the challenge of assessing patients with pre-existing neurological diseases who have contracted SARS-CoV-2, patients with COVID-19 who present neurological emergencies, and patients who are carriers of the virus and have developed secondary neurological complications, either during the course of the disease or after it. Some authors and recent literature reports suggest that the presence of neurological manifestations in patients who are carriers of SARS-CoV-2 may be associated with a greater severity of the disease.
新型冠状病毒肺炎(COVID-19)的临床表现让人联想到细胞因子释放综合征和继发性噬血细胞性淋巴组织细胞增生症所诱发的急性呼吸窘迫综合征,后者在感染严重急性呼吸综合征冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV)等其他冠状病毒的患者中可见。神经科医生面临着评估以下几类患者的挑战:感染了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的患有基础神经疾病的患者、出现神经急症的COVID-19患者,以及在疾病过程中或之后成为病毒携带者并出现继发性神经并发症的患者。一些作者和近期的文献报告表明,SARS-CoV-2携带者出现神经表现可能与疾病的更严重程度相关。